Metabolic Response to an Individualized Multimodal Treatment Strategy in Advanced Pancreatic Adenocarcinoma: A Case Report
Current Oncology · 19.08.2026 · 33 (8) · 489
DOI: 10.3390/curroncol33080489 ↗Kurz gefasst
Fallbericht in der Zeitschrift Current Oncology, online erschienen am 19.08.2026. Verfasst von Mehmet Salih İyikesici und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neolife Oncology Centre, 34340 Istanbul, Türkiye. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metastatic pancreatic adenocarcinoma carries a dismal prognosis, and treatment options after progression on standard chemotherapy remain limited. We report a metabolic response in a patient with drug-resistant disease treated with a combined multimodal regimen that paired dose-reduced (“activated”) multi-agent chemotherapy with targeted agents and metabolic/microenvironmental support, set against an unusually long overall survival. Case Presentation: A 46-year-old man was diagnosed with inoperable, locally advanced/stage IV pancreatic adenocarcinoma in June 2023 and maintained disease control for approximately 2.5 years on a combined multimodal regimen, termed here metabolically controlled oncologic therapy (MCOT): dose-reduced chemotherapy given with regional hyperthermia, hyperbaric oxygen, and a carbohydrate-restricted diet. In February 2026 he developed local recurrence and diffuse liver metastases, and by May 2026 had deteriorated rapidly, with 18F-FDG PET/CT showing a peak SUVmax of 18.2 and CA 19-9 of 2788 U/mL. His regimen was intensified to a low-dose, multi-agent “activated” chemotherapy protocol combined with lenvatinib, everolimus, hyperthermia, and hyperbaric oxygen. Clinical Findings and Outcomes: One month later, his performance status had recovered from ECOG PS 2 to PS 0, CA 19-9 was 31 U/mL, and follow-up PET/CT showed a 63.7% decrease in SUVmax (from 18.2 to 6.6). Treatment-related adverse events included Grade 1 nausea, Grade 1 vomiting, and thrombocytopenia; no Grade 2 or higher non-hematological toxicity was observed.
Conclusions
In selected patients who are considered to have exhausted standard options, a combined multimodal regimen pairing dose-reduced chemotherapy with metabolic and microenvironmental support may produce a well-tolerated metabolic response. As a single, uncontrolled observation, these findings cannot establish causality and require confirmation in prospective, controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neolife Oncology Centre, 34340 Istanbul, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Division of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Türkiye.
- Department of Basic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.
- Medical School, Kings College of London, London WC2R 2LS, UK.
- Department of Biology, Boston College, Boston, MA 02467, USA.
ORCID-Profile: Mehmet Salih İyikesici, Sena Şen, Selin Oncul, Tomas Duraj, Thomas N Seyfried
Zitieren
APA
İyikesici, M. S., Oncul, O., Hallaç, M., Şen, S., Taflan, Ş., Oncul, S., Duraj, T., & Seyfried, T. N. (2026). Metabolic Response to an Individualized Multimodal Treatment Strategy in Advanced Pancreatic Adenocarcinoma: A Case Report. Current Oncology, 33(8), 489. https://doi.org/10.3390/curroncol33080489
Vancouver
İyikesici MS, Oncul O, Hallaç M, Şen S, Taflan Ş, Oncul S, et al. Metabolic Response to an Individualized Multimodal Treatment Strategy in Advanced Pancreatic Adenocarcinoma: A Case Report. Current Oncology. 2026;33(8):489. doi:10.3390/curroncol33080489
BibTeX
@article{yikesici2026,
author = {İyikesici, Mehmet Salih and Oncul, Oral and Hallaç, Metin and Şen, Sena and Taflan, Şirin and Oncul, Selin and Duraj, Tomas and Seyfried, Thomas N},
title = {Metabolic Response to an Individualized Multimodal Treatment Strategy in Advanced Pancreatic Adenocarcinoma: A Case Report},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {8},
pages = {489},
doi = {10.3390/curroncol33080489}
}
EUVIMED